This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Methods Relevant studies examining arrhythmia in both exercise and pharmacological stress testing were searched for in PubMed, Embase and Cochrane databases from inception to 14 June 2023. The primary outcomes of interest were mortality in ventricular and atrial arrhythmias, and later diagnosis of cardiac disease in atrial arrhythmias.
The registry will collect multi-site, real-world information on how the Plaque Analysis product provides enhanced patient insights, empowering physicians and helping to inform their medical management decisions for patients with suspected coronaryarterydisease (CAD). Observed outcomes and biomarkers are secondary endpoints.
In 2024, the FDA approved Flyrcado for patients with known or suspected coronaryarterydisease (CAD), delivering higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) i myocardial perfusion imaging (MPI), the predominant procedure used in nuclear cardiology today. 2023 Oct, 82 (16) 15981610.
Background The prognosis of myocardial ischaemia with no obstructive coronaryarterydisease (INOCA) and its underlying vasomotor disorders, vasospastic angina (VSA) and microvascular angina (MVA), is not well defined. Results Fifty-four studies (17 302 patients) meeting the eligibility criteria were selected.
A common feedback I get is that people with existing coronaryarterydisease feel like it doesn’t apply to them. Arguably, applying the principles of prevention offers more bang for buck in the short term for people WITH coronaryarterydisease than those without coronaryarterydisease.
v As cardiovascular disease (CVD) continues to rise globally, vi the need for advanced diagnostic technologies like cardiac CT angiography (CCTA) becomes increasingly critical. CCTA offers a non-invasive, cost-effective, and highly sensitive method for diagnosing coronaryarterydisease (CAD), making it a valuable tool for clinicians.
Coronaryarterydisease is caused by the retention of a cholesterol particle in the artery wall. Insulin resistance and diabetes may not ‘ cause ’ coronaryarterydisease, but they are huge accelerants. If delaying the onset of major chronic disease is your goal. Timing Matters.
With more than 500 peer-reviewed publications, the HeartFlow FFR CT Analysis remains unparalleled in precision coronary care, as supported by the ACC/AHA Chest Pain Guidelines, to improve treatment plans and outcomes. REVEALPLAQUE Study, SCCT 2023. said John Farquhar, Chief Executive Officer at HeartFlow. Data on file.
MILLER, PHD, LED THE DEVELOPMENT OF A NEW "ATHEROSCLEROSIS ATLAS" THAT DETAILS, AT THE LEVEL OF INDIVIDUAL CELLS, CRITICAL PROCESSES RESPONSIBLE FOR FORMING THE HARMFUL PLAQUE BUILDUP THAT CAUSES HEART ATTACKS, STROKES AND CORONARYARTERYDISEASE.
Our efforts to expand therapeutic possibilities, underlined by the introduction of the Freesolve RMS for coronaryarterydisease treatment, will continue in the BTK indication with this groundbreaking innovation.” Eurointervention; 2023;18-online publish-ahead-of-print January 2023. 4 Seguchi M.,
Publication date: Available online 19 November 2023 Source: The American Journal of Cardiology Author(s): Yuko Kiyohara, Tadao Aikawa, Keigo Kayanuma, Hisato Takagi, Polydoros N. Kampaktsis, Jose Wiley, Toshiki Kuno
Cardiac amyloidosis is a heterogeneous disease that results from the accumulation of abnormal proteins within the heart, impairing its ability to pump blood. Over time, the build-up of these proteins causes the heart muscle to stiffen, eventually leading to heart failure, which can have dire outcomes if not found early.
We evaluated patterns of evidence-based prescription of SGLT2i and GLP1RA over time and by race in US Veterans with T2D and coronaryarterydisease (CAD).Results:Of We evaluated patterns of evidence-based prescription of SGLT2i and GLP1RA over time and by race in US Veterans with T2D and coronaryarterydisease (CAD).Results:Of
Guideline-directed medical therapy (GDMT) for HF has shown benefits on outcomes. Methods and results Between 2012 and 2023, 408 patients admitted for HF with a LV ejection fraction (LVEF) of 40% or less and documented coronaryarterydisease (CAD) were included. After a median 44.6-month
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronaryarterydisease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Methods Patients with symptomatic PAF who underwent RFCA between October 2021 and May 2023 were retrospectively analysed. Compared with the PVI group, patients in the PVI+SVCI group had a higher prevalence of coronaryarterydisease (p=0.04), stroke (p=0.02) and a smaller left atrial diameter (p<0.01).
This study aims to investigate the relationship between sdLDLC level and PP in patients with stable coronaryartery disease.MethodsWe conducted a retrospective analysis of 146 lesions in 86 patients by repeat intravascular ultrasound examinations from January 2020 to May 2023.
Background There is mounting data supporting the use of drug-coated balloons (DCB) not only for treatment of in-stent restenosis (ISR), but also in native coronaryarterydisease. Angiograms and outcomes were independently adjudicated. So far, paclitaxel-coated balloons represented the mainstay DCBs. IQR 12; 14.2)
Cardiovascular medications frequently lead this category, often contributing to adverse clinical outcomes, including emergency department visits and hospitalizations. American Geriatrics Society 2023 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Circulation. 2016;134(6):e32-69.
Between 2020 and 2023, the rates of obesity dropped by about 2% 2. Inflammation is a key driver of heart disease, specifically coronaryarterydisease. Sci Rep 13 , 20998 (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. 2023 Dec 14;389(24):2221-2232. Inflammation.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Diabetes is a risk factor for acute ischemic stroke and also a poor predictor of outcome for many interventional surgeries. We performed this retrospective cohort analysis to assess the impact of poorly controlled diabetes, defined as HbA1C of 9.0%
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. This study presented two patients with symptomatic common carotid artery occlusion (CCAO) who subsequently underwent subclavian‐carotid artery bypass surgery using the polytetrafluorethylene graft.
An elevated Lp(a) is a common genetic factor that is independently and causally related to premature coronaryarterydisease. The occurrence of disease in this instance is probabilistic, not deterministic. An elevated Lp(a) does increase the risk of early cardiovascular disease, but that risk is not set in stone.
More past history: hypertension, tobacco use, coronaryarterydisease with two vessel PCI to the right coronaryartery and circumflex artery several years prior. It is unknown when this pain recurred and became constant. He reports feeling nauseated with emesis. There is ischemic ST depression in V4-V6.
Abstract: Colchicine reduces atherothrombotic cardiovascular events in coronaryarterydisease (CAD) due to its anti-inflammatory effect. The primary outcome was the percentage change in hsCRP levels at the end of four weeks. The primary outcome was the percentage change in hsCRP levels at the end of four weeks.
In the early years of percutaneous coronary intervention (PCI), studies indicated a heightened risk of major adverse cardiac events (MACE) in patients with reduced left ventricular ejection fraction (LVEF), involving outcomes such as death, Q-wave myocardial infarction (MI), stent thrombosis, and repeat revascularization. Am Heart J.
Soviet biologist Trofim Lysenko famously rejected the objective reality of Mendelian genetics because it clashed with the Marxist philosophy that the environment, not genetics, was the primary determinant of outcomes. But what should matter is outcomes not diagnoses. Thanks for reading Dr. Anish Koka's Newsletter!
Regardless of what is driving the effect, it is clear that experiencing high levels of stress is associated with worse outcomes. 24% increased risk of coronaryarterydisease. While studies attempt to correct for these influences, it can be very hard to do. These findings have been replicated multiple times.
A 56 year old male with a history of diabetes, dyslipidemia, hypertension, and coronaryarterydisease presented to the emergency department with sudden onset weakness, fatigue, lethargy, and confusion. For more on use of Opiates with acute ischemic CP — See the January 6, 2023 post in Dr. Smith's ECG Blog ).
Methods A total of 685 patients diagnosed with STEMI, treated with emergency PCI between January 2020 and June 2023, were included in this retrospective observational study. Objective This study aims to assess the relationship between serum iron levels and in-hospital mortality among patients with STEMI undergoing emergency PCI. μmol/L).
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Outcomes of interest included symptomatic intracerebral hemorrhage (ICH), asymptomatic ICH, hemorrhagic transformation, mass effect and death. IntroductionThe risk of tandem occlusion treatment in the setting of intravenous thrombolysis is unclear.
An elevated Lp(a) is independently and causally related to early: Coronaryarterydisease Stroke Peripheral Vascular Disease Aortic Stenosis For a more comprehensive review of what Lp(a) is and why it matters, I have covered this in much more detail here. Subscribe now 1 ODYSSEY Outcomes Committees and Investigators.
Angiogram No obstructive epicardial coronaryarterydisease Cannot exclude non-ACS causes of troponin elevation including coronary vasospasm, stress cardiomyopathy, microvascular disease, etc. Myocardial Infarction With Nonobstructive CoronaryArteries (MINOCA): The Past, Present, and Future Management [Internet].
Old ‘NSTEMI’ A history of coronaryarterydisease and a stent to the same territory further increases pre-test likelihood of acute coronary occlusion, including in-stent thrombosis. This 4% is underestimation because it only included patients admitted as STEMI not those admitted as NSTEMI like the case above.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Early diagnosis and appropriate treatment are crucial to reduce burden of poor outcomes and prevention of stroke.
Share Let’s first state our goal when we are in the business of ‘Heart Disease Prevention’: To delay the onset of coronaryarterydisease (atherosclerosis/plaque) that might rupture and cause a heart attack. So, we now know that achieving fewer METs is associated with worse outcomes. Not any more.
This was a huge gap, because most patients with T2DM die from cardiovascular disease, and until recently, we had no means of preventing adverse cardiovascular events in these patients. Cardiovascular outcomes trials with SGLT-2 inhibitors have shown a strong effect in preventing major cardiovascular events (i.e., Lavie, Carl J.,
2024 STS Coronary Conference Submission Information gtrainyte Wed, 02/07/2024 - 14:48 Scroll to top Important Visit sts.org to access the submission site. All submissions should be related to surgery for coronaryarterydisease. No abstract will be considered with deferred outcomes data.
The scan showed a bicuspid aortic valve with severe stenosis and coronaryarterydisease. Severe AS markedly complicates management and portends poorer longterm outcome when associated with acute MI ( Abraham et al Cath Cardiovasc Interv 102(1): 159-165, 2023 Paquin et al Open Heart 9(1):e002046, 2022 ).
Was her outcome to be expected for ostial RCA OMI? Circumstances attending 100 sudden deaths from coronaryarterydisease with coroners necropsies. The patient certainly had OMI and received treatment for it. There is no specific treatment for stress cardiomyopathy, only supportive treatment. link] Jentzer, J. Kashou, A.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content